FENC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FENC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Fennec Pharmaceuticals is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, Fennec Pharmaceuticals's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Fennec Pharmaceuticals's Risk Assessment falls into.
Fennec Pharmaceuticals (NAS:FENC) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Robert Andrade | officer: Chief Financial Officer | C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
Rosty Raykov | director, officer: Chief Executive Officer | C/O ADHEREX TECHNOLOGIES INC., 4620 CREEKSTONE DRIVE, SUITE 200, DURHAM NC 27703 |
Chris A Rallis | director | C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560 |
Adrian Haigh | director | 83 ANGLESSA ROAD, BALLSBRIDGE, DUBLIN L2 D04H27 |
Marco Maria Brughera | director | VIALE STEFINI 14, MILANO L6 00000 |
Khalid Islam | director | C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950 |
Shubh Goel | officer: Chief Commercial Officer | 1100 MAXWELL, #522, HOBOKEN NJ 07030 |
Southpoint Capital Advisors Lp | 10 percent owner | 1114 AVENUE OF THE AMERICAS, 22ND FLOOR, NEW YORK NY 10036 |
Spa Essetifin | 10 percent owner | VIA SUDAFRICA 20, ROME L6 00144 |
Jodi A Cook | director | PO BOX 816, NEWTOWN PA 08540 |
Manchester Management Pr, Llc | 10 percent owner | 3 WEST HILL PLACE, BOSTON MA 02114 |
Francesca Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Paolo Cavazza | 10 percent owner | VIA TESSERETE, 10, LUGANO V8 V8 |
Silvia Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
Enrico Cavazza | 10 percent owner | VIA PONTINA KM 30,400, POMEZIA (ROME) L6 00040 |
From GuruFocus
By sperokesalga sperokesalga • 05-08-2023
By GuruFocusNews GuruFocusNews • 07-01-2022
By Value_Insider Value_Insider • 11-11-2022
By Stock market mentor Stock market mentor • 01-31-2023
By Marketwired • 09-07-2023
By Stock market mentor Stock market mentor • 01-25-2023
By Marketwired • 08-03-2023
By GlobeNewswire • 07-31-2023
By sperokesalga sperokesalga • 06-12-2023
By GuruFocusNews GuruFocusNews • 06-21-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.